Patents Assigned to Université de Paris
  • Patent number: 11852704
    Abstract: The present disclosure is directed to a motor for a magnetic resonance (MR) tomography room, to a patient table for the MR room, to a MR elastography device, and to a MR tomography device. A MR tomography device for a MR elastography imaging protocol is arranged within the MR tomography room, and includes a rotational drive for supplying rotational energy to power a MR elastography transducer usable during the MR elastography imaging protocol, and a support structure. The rotational drive comprises a terminal for connecting the MR elastography transducer to the rotational drive, and a bearing means configured such that the position of the terminal relative to the support structure is adaptable along a trajectory predetermined by the bearing means. The rotational drive is mounted to the support structure via the bearing means.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: December 26, 2023
    Assignees: Siemens Healthcare GmbH, Centre National de la Recherche Scientifique (CNRS), Institut National de La Sante et de la Recherche Medicale (INSERM), King's College London, Department of Health and Human Services, UNIV PARIS XIII PARIS-NORD VILLETANEUSE, Universite de Paris
    Inventors: Giacomo Annio, Verena Muller-Reinwald, Ralph Sinkus, Omar Darwish, Wilfried Schnell, Tamara Elisabeth Falkner, Ahmed M. Gharib
  • Patent number: 11854801
    Abstract: A method for depositing an object, including: —approaching, in an enclosure, a holder in the direction of a carrier substrate, then—transferring, in the enclosure, the object from the holder to an area for depositing the carrier substrate. The transfer step is preferably carried out when the inside of the enclosure is in a vacuum at a pressure below 10?6 bar.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: December 26, 2023
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ECOLE NORMALE SUPERIEURE, SORBONNE UNIVERSITE, UNIVERSITE DE PARIS
    Inventors: Matthieu Delbecq, Tino Cubaynes, José Palomo, Matthieu Dartiailh, Takis Kontos, Matthieu Desjardins
  • Patent number: 11757168
    Abstract: A method for manufacturing a superconducting LC-type resonator of the type including at least one high-resistivity substrate on which are printed an inductive meander, a first so-called lower electrode and a second so-called upper electrode arranged opposite the first so as to form together a capacitor connected in parallel with the inductive meander, as well as inductive coupling means dedicated to the resonator, in which a sacrificial aluminium layer is deposited between the first and second electrodes. Also disclosed is the superconducting LC-type resonator thus obtained and the use of such a resonator for detecting the noise of a millimetre photon.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: September 12, 2023
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, OBSERVATOIRE DE PARIS, CY CERGY PARIS UNIVERSITÉ, SORBONNE UNIVERSITE, UNIVERSITÉ DE PARIS
    Inventors: Faouzi Boussaha, Samir Beldi, Christine Chaumont, Thibaut Vacelet
  • Patent number: 11723956
    Abstract: The present invention concerns a thermosensitive polymeric hydrogel comprising at least one thermosensitive copolymer, one aqueous solution, and a mucoadhesive excipient, wherein said thermosensitive polymeric hydrogel further comprises at least one immunostimulatory adjuvant and/or at least one cytokine and/or at least one chemokine and/or atleast one heat shockprotein. Another object of the invention is a thermosensitive polymeric hydrogel according to the invention for use in the treatment of tumors or metastasis in a subject having a cancer, preferably a metastatic cancer.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: August 15, 2023
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université de Paris, Assistance Publique—Hopitaux de Paris, Ecole Nationale Superieure de Chimie de Paris, Universite de Versailles—St. Quentin en Yvelines
    Inventors: Robert Malafosse, Nathalie Mignet, Vincent Boudy, Johanne Seguin, Kathia Lemdani, Claude Capron
  • Patent number: 11642376
    Abstract: The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydro-carbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: May 9, 2023
    Assignees: Assistance Publique—Hopitaux de Paris, Fondation Imagine—Institut des Maladies Génétiques, Université de Paris Cité, Institut National de la Santé et de la Recherche Médicale (INSERM)
    Inventors: Isabelle André, Marina Cavazzana, Kuiying Ma, John Tchen, Tayebeh-Shabi Soheili, Ranjita Devi Moirangthem
  • Patent number: 11644422
    Abstract: A calibration standard for determining an intensity decay related to an evanescent field generated close to the interface between a sample to be tested and a substrate on which the sample is to be deposited, preparation and analysis methods and use thereof.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: May 9, 2023
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE PARIS, UNIVERSITE BAR-ILAN
    Inventors: Martin Oheim, Adi Salomon
  • Patent number: 11617748
    Abstract: The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to the inflammation induced by P. acnes, in particular in the prevention and/or the treatment of acne, psoriasis, chronic urticaria, urticaria pigmentosa, cutaneous autoinflammatory diseases, hidradenitis or atopic dermatis.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: April 4, 2023
    Assignees: Universite de Paris, Assistance Publique—Hopitaux de Paris
    Inventors: Nicolas Dupin, Vincent Calvez, Philippe Grange, Anne-Geneviève Marcelin
  • Patent number: 11609124
    Abstract: A method for determining wavefront shapes of N angular channels CL of different propagation directions PL, said propagation directions PL being determined by a mean propagation direction vector , from a single signal image acquisition I(x,y) of a multi-angular signal light beam containing said angular channels, each angular channel Ci being separated from other angular channels Cj by an angular separation ??ij defined by ??ij=arccos, where “·” stands for the inner product between and .
    Type: Grant
    Filed: September 28, 2021
    Date of Patent: March 21, 2023
    Assignees: UNIVERSITE DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), SORBONNE UNIVERSITE
    Inventors: Marc Guillon, Gilles Tessier, Tengfei Wu, Pascal Berto
  • Publication number: 20230054300
    Abstract: The present application relates to a double-stranded DNA molecule comprising a first double-stranded DNA molecule (1) connected to a second double-stranded DNA molecule (2) by at least one covalent bond which is not a phosphodiester, phosphorothioate, phosphoramidate or phosphorodiamidate bond, preferably by a tether, said tether preferably being a double-stranded DNA molecule.
    Type: Application
    Filed: December 21, 2018
    Publication date: February 23, 2023
    Applicants: PARIS SCIENCES ET LETTRES - QUARTIER LATIN, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ECOLE NORMALE SUPERIEURE, UNIVERSITÉ DE PARIS
    Inventors: Térence STRICK, Charlie GOSSE, Dorota KOSTRZ, Jinglong WANG, Marc NADAL
  • Patent number: 11573241
    Abstract: The present invention relates to a novel use of total cellular iron, preferably under the form of ferrous iron (Fe2+), as a marker of cancer stem cells (CSCs). The invention also relates to methods using said iron marker, in particular for metastatic cancer diagnosis or treatment, for screening for compounds of interest, as well as for killing CSCs.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: February 7, 2023
    Assignees: Institute National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université de Paris
    Inventors: Maryam Mehrpour, Raphael Rodriguez, Ahmed Hamai, Trang Mai
  • Publication number: 20220356520
    Abstract: The present invention relates to a digital multiplex method for detecting and/or quantifying multiple target biomolecules in a sample, said biomolecules being selected from DNA, RNA, and proteins. The present invention further relates to different applications of the digital multiplex method and to a kit.
    Type: Application
    Filed: May 27, 2020
    Publication date: November 10, 2022
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS, PARIS SCIENCES ET LETTRES, UNIVERSITE DE PARIS
    Inventors: Guillaume GINES, Yannick RONDELEZ, Thomas JET, Valérie TALY
  • Publication number: 20220334078
    Abstract: An organic electrochemical transistor, which includes a biologic detection layer and a catalytic layer, the latter being a composite material including noble metal nanoparticles and an organic conductive matrix. Also, a method for detection of a biological analyte wherein a biological fluid is contacted with such an organic electrochemical transistor.
    Type: Application
    Filed: September 23, 2020
    Publication date: October 20, 2022
    Applicants: VALOTEC, UNIVERSITE DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Dany CAPITAO, Antoine MAURIN, Caroline ABREU, Vincent NOËL, Giorgio MATTANA
  • Publication number: 20220333177
    Abstract: The present invention relates to a digital method for detecting and/or quantifying at least one target biomolecules in a sample, said biomolecules being selected from DNA, RNA, and proteins based on isothermal amplification. The present invention further relates to different applications of the digital method and to a kit.
    Type: Application
    Filed: May 27, 2020
    Publication date: October 20, 2022
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS, PARIS SCIENCES ET LETTRES, UNIVERSITE DE PARIS
    Inventors: Yannick RONDELEZ, Guillaume GINES, Roberta LIMA DE CASTRO MENEZES, Valérie TALY
  • Patent number: 11471113
    Abstract: A method for determining a health status of a system of interest is proposed. The method comprises acquiring (S1) a time series, extracting (S2) subsequences, selecting (S3) a set of subsequences, classifying (S4) the subsequences of the set into several groups on the basis of at least one criterion of resemblance to at least one reference subsequence, and constructing (S5) a normal operating model of the system of interest. The construction includes, for each group, a modeling (S51) of a representative subsequence and a determination (S52) of an associated weight. The normal model is defined by the modeled subsequences and the associated weights. The method further includes an attribution (S6) of a normality score to each subsequence extracted by comparison with the normal model, an identification (S7) of at least one abnormal subsequence, and a determination (S8) of the health status of the system of interest.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: October 18, 2022
    Assignees: UNIVERSITÉ DE PARIS, ÉLECTRICITÉ DE FRANCE
    Inventors: Themis Palpanas, Michele Linardi, Paul Boniol, Federico Roncallo, Mohammed Meftah, Emmanuel Remy
  • Patent number: 11473145
    Abstract: The inventors initially participated to the identification of LPIN1 mutations as a cause for massive rhabdomyolysis episodes in children, triggered by febrile illness. The inventors have suggested that TLR9 antagonists would be suitable for the treatment of rhabdomyolysis (WO2017085115). The inventors thus treated 2 patients with lipin-1 disease by a TRL9 antagonist (hydroxychloroquine). They showed that the accumulation of mtDNA in plasma of the two patients before treatment decreases under treatment. When the treatment was stopped, the accumulation of mtDNA reappeared, then normalized when treatment was resumed. Accordingly, the present invention relates to a method for determining whether a patient suffering from rhabdomyolysis achieves a response with a TLR9 antagonist comprising determining the amount of mitochondrial DNA (mtDNA) in a blood sample obtained from the patient (e.g. by PCR).
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: October 18, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), FOUNDATION IMAGING, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ DE PARIS
    Inventors: Pascale De Lonlay-Debeney, Peter Van Endert, Marine Madrange, Yamina Hamel, François-Xavier Mauvais
  • Publication number: 20220328137
    Abstract: The invention concerns a method determining an optimum drug dosing regimen to treat a patient efficiently against drug-sensitive pathogenic agents. From relevant patient-related data and the drug concentration measured at a random time in the patients body, the method estimates the drug concentration time-course based on a Bayesian model. The residual concentration (Cr) and an efficiency pharmacokinetic parameter (PPE) adapted to said drug and patient are computed from the estimated concentration. A dosing regimen is then determined by comparing the PPE to an efficiency target (CE) for efficiency purposes. The method further may further take into account toxicity constraints by comparing the residual drug concentration (Cr) to at least a toxic concentration (Ctox). A concentration of said drug is determined (E13) based on the result the above comparisons to provide a proposed dose for said optimum dosing regimen.
    Type: Application
    Filed: June 8, 2020
    Publication date: October 13, 2022
    Applicants: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, UNIVERSITE DE PARIS
    Inventors: Déborah Hirt, Nedjma Sihem Benaboud, Naïm Bouazza, Jean-Marc Treluyer
  • Patent number: 11451722
    Abstract: The invention relates to a method for acquiring an image by an imager (20) comprising a matrix of pixels configured to generate an electric response when exposed to an incident light flux travelling through an optical path (21) in which is arranged a wavefront correction element (22), comprising the following steps: 1) initiating the exposure of the pixels to the incident light flux; 2) for a plurality of iterations during the exposure: 2.1) non-destructive reading of the electric responses of pixels of a region of interest; 2.2) determining an evolution of the spatial distribution of pixels in logarithmic mode previous iteration with respect to the previous iteration; 2.3) based on said evolution, establishing a command for the wavefront correction element (22) in order to correct the wavefront; 2.4) configuring the wavefront correction element, 3) reading the electric responses of the pixels resulting in an image.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: September 20, 2022
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, SORBONNE UNIVERSITE, ECOLE NORMALE SUPERIEURE, UNIVERSITE DE PARIS, UNIVERSITE DE BOURGOGNE, OBSERVATOIRE DE PARIS
    Inventors: David Darson, Julien Dubois, Francois Colas
  • Publication number: 20220280655
    Abstract: Adeno-associated virus (AAV) is a defective mono-stranded DNA virus, endemic in human population (35-80%). Recurrent clonal AAV2 insertions are associated with the pathogenesis of rare human hepatocellular carcinoma (HCC) developed on normal liver. The aimed of the inventors was to characterize the natural history of AAV infection in the liver. Viral DNA was thus quantified in tumor and non-tumor liver tissues of 1461 patients. Presence of episomal form and viral mRNA expression were analyzed using a DNAse/TaqMan based assay and quantitative RT-PCR. In silico analyses using viral capture data explored viral variants and new clonal insertions. AAV DNA was detected in 21% of the patients equally distributed in 2 major viral subtypes: one similar to AAV2, the other hybrid between AAV2 and AAV13 sequences. Thus the inventors provided an integrated analysis of the wild type AAV infection in the liver with the identification of viral genotypes, molecular forms, helper virus relationship and viral integrations.
    Type: Application
    Filed: April 23, 2020
    Publication date: September 8, 2022
    Applicants: Institut National de la Santé et de la Recherche Médicale, Assistance Publique-Hôpitaux de Paris, Genethon, Sorbonne Université, Universite de Paris, Université d'Evry-Val-d'Essonne, Universite Paris XIII Paris-Nord Villetaneuse
    Inventors: Jessica Zucman-Rossi, Jean-Charles Nault, Tiziana La Bella, Giuseppe Ronzitti, Sandrine Imbeaud, Patrice Vidal
  • Publication number: 20220275105
    Abstract: A method for providing cardioprotection in a subject who experienced a myocardial infarction, including administering a therapeutically effective amount of a Granzyme B inhibitor. Following acute MI in mice, CD8+ T lymphocytes are quickly recruited and activated in ischemic heart tissue, and release Granzyme B, leading to cardiomyocyte apoptosis and deterioration of myocardial function. Antibody-mediated depletion of CD8+ T lymphocytes decreases Granzyme B content and apoptotic within the myocardium and inflammatory response. mAb mediated-CD8 depletion limits myocardial injury and improves heart function. These effects are recapitulated in mice with CD8+ T cell selective Granzyme B deficiency in mice. Granzyme B is produced by other cell types (e.g., NK cells). Global Granzyme B deletion (GzmB-/- mice) decreases apoptotic within the myocardium, reduces local pro-inflammatory signature and ultimately limits infarct size after MI.
    Type: Application
    Filed: July 31, 2020
    Publication date: September 1, 2022
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), SORBONNE UNIVERSITÉ, UNIVERSITÉ DE PARIS
    Inventors: Hafid AIT-OUFELLA, Nicolas DANCHIN, Icia SANTOS ZAS, Tabassome SIMON
  • Publication number: 20220251232
    Abstract: Novel anti-CD25 antibodies and antigen-bind fragments thereof that do not inhibit the binding of interleukin-2 (IL-2) to CD25, and the use thereof for treating cancer or an infectious disease. Also, fusion proteins including the antibodies and antigen-bind fragments, nucleic acids encoding the antibodies and antigen-bind fragments, and an expression vectors including the nucleic acids. Further, pharmaceutical compositions including the fusion proteins or the antibodies and antigen-bind fragments.
    Type: Application
    Filed: May 20, 2020
    Publication date: August 11, 2022
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ D'AIX MARSEILLE, UNIVERSITE DE PARIS, ALDERAAN BIOTECHNOLOGY, UNIVERSITE PARIS EST CRETEIL VAL DE MARNE
    Inventors: Daniel OLIVE, Armand BENSUSSAN, Jérôme GIUSTINIANI, Arnaud FOUSSAT